1-5 of 5
Rina Hui
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Rina Hui, Alex Pearson, Javier Cortes, Christine Campbell, Camille Poirot, Hatem A. Azim, Jr, Debora Fumagalli, Matteo Lambertini, Fergus Daly, Amal Arahmani, José Perez-Garcia, Philippe Aftimos, Philippe L. Bedard, Laura Xuereb, Elsemieke D. Scheepers, Malou Vicente, Theodora Goulioti, Sibylle Loibl, Sherene Loi, Marie-Jeanne Pierrat, Nicholas C. Turner, Fabrice Andre, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 354–363.
https://doi.org/10.1158/1078-0432.CCR-19-1164
Published: 15 January 2020
View article titled, Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Open the PDF for Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study in another window
Includes: Supplementary data
Journal Articles

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

Peter Fox, Rosemary L. Balleine, Clara Lee, Bo Gao, Bavanthi Balakrishnar, Alexander M. Menzies, Shang Heng Yeap, Sayed Sahanawaz Ali, Val Gebski, Pamela Provan, Sally Coulter, Christopher Liddle, Rina Hui, Richard Kefford, Jodi Lynch, Mark Wong, Nicholas Wilcken, Howard Gurney
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (13): 3164–3171.
https://doi.org/10.1158/1078-0432.CCR-15-1470
Published: 30 June 2016
View article titled, Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study
Open the PDF for Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study in another window
Includes: Supplementary data
Journal Articles

Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.

Edward B. Garon, Ani Balmanoukian, Omid Hamid, Rina Hui, Leena Gandhi, Natasha Leighl, Matthew Gubens, Jonathan W. Goldman, Gregory M. Lubiniecki, Kenneth Emancipator, Marisa Dolled-Filhart, Jared Lunceford, Kevin Gergich, Naiyer A. Rizvi
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2_Supplement): A20.
https://doi.org/10.1158/1078-0432.14AACRIASLC-A20
Published: 16 January 2014
View article titled, Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.
Journal Articles

INK4a Gene Expression and Methylation in Primary Breast Cancer: Overexpression of p16INK4a Messenger RNA Is a Marker of Poor Prognosis

Rina Hui, R. Douglas Macmillan, Frances S. Kenny, Elizabeth A. Musgrove, Roger W. Blamey, Robert I. Nicholson, John F. R. Robertson, Robert L. Sutherland
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2777–2787.
Published: 01 July 2000
View article titled, <em>INK4a</em> Gene Expression and Methylation in Primary Breast Cancer: Overexpression of p16<sup>INK4a</sup> Messenger RNA Is a Marker of Poor Prognosis
Open the PDF for <em>INK4a</em> Gene Expression and Methylation in Primary Breast Cancer: Overexpression of p16<sup>INK4a</sup> Messenger RNA Is a Marker of Poor Prognosis in another window
Journal Articles

Overexpression of Cyclin D1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer

Frances S. Kenny, Rina Hui, Elizabeth A. Musgrove, Julia M.W. Gee, Roger W. Blamey, Robert I. Nicholson, Robert L. Sutherland, John F. R. Robertson
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (8): 2069–2076.
Published: 01 August 1999
View article titled, Overexpression of Cyclin D1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer
Open the PDF for Overexpression of Cyclin D1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer in another window